> ANX rising very high. More good news coming. Buy ANX. It can hit $5
> soon.

> TLCV is a $300 million eye care company. It is North America's first
> eye care company, providing doctors with the tools and technologies
> needed to deliver high-quality patient care.

> TLCV maintains leading positions in $2.8 billion and $5.6 billion U.S.
> industry involving refractive and cataract, which is one of the
> world's most widely performed procedure.

> Buy TLCV. Their financial report will be in the news on May 14.  TLCV
> can hit $5 soon

> http://www.tlcv.com/default.asphttp://www.tlcv.com/about/

> My business expert bought 400,000 shares of NEXM. He says NEXM will
> hit $5 soon.

> NEXM is a good investment

> NexMed (NEXM) is a pharmaceutical and medical technology company that
> focuses on developing and commercializing therapeutic products. This
> excellent drug developer has a significant range of innovative
> pharmaceutical products that solves a host of medical needs. The
> Company's new products are based on an enhancement drug technology
> known as NexACT, which can enable an active drug to function
> effectively.

> * NexAct Technology

> NEXM drug technology - NexACT - represents an important breakthrough
> in providing a highly effective therapeutic approach. The patented
> NexACT technology utilizes highly effective formulations. The NexACT
> system can create new products that not only provide patients with
> added therapeutic benefits, but also extend the product life for an
> additional 20 years under the multiple patent protection of the NexACT
> technology.

> * Commercial Potential

> NEXM produces Vitaros serving over 200 million people worldwide. In
> addition, the current treatment market is estimated at $3 billion
> worldwide and is projected to expand to $5 billion.

> NEXM is also producing more than $150 billion brand-name drug
> products. This represents a significant opportunity for converting
> some of those products for better patient compliance or for added
> therapeutic benefit.

> http://www.google.com/finance?q=nexmhttp://www.nexmed.com/technology/...

> I think the reason for the huge price and volume increase is due to
> one or more instituional buyers acumulating the stock. they are buying
> 200,000 to 300,000 shares a day and before this run there were weeks
> with only 30,000-60,000 volume a day. Why they are buying is the
> important question, what do they know that we don't, we can probably
> assume it is good news but how good and what. I still think a buyout
> is a posibility but they could just have had great results this
> quarter and the numbers are leaking out. Either way I don't expect we
> will hear anything until earnings are reported this month around the
> 24th.